Robert A. Kyle, MD
Disclaimer: This editorial does not imply that Mayo Foundation endorses any of the products mentioned therein.
Disclosure: Dr. Kyle is on the Speaker's Bureau of OrthoBiotech, Schering-Plough, and Novartis. He also serves as a consultant to Hoffman-LaRoche.
Grant Support: In part by National Cancer Institute grant CA62242.
Requests for Single Reprints: Robert A. Kyle, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, email@example.com.
Kyle R.; The Role of Bisphosphonates in Multiple Myeloma. Ann Intern Med. 2000;132:734-736. doi: 10.7326/0003-4819-132-9-200005020-00009
Download citation file:
Published: Ann Intern Med. 2000;132(9):734-736.
Multiple myeloma is characterized by bone destruction that often leads to some of the most debilitating manifestations of this disease: pain, hypercalcemia, osteopenia, pathologic fractures, and spinal cord compression. These clinical manifestations are due not only to myeloma deposits in the bone, which lead to focal bone destruction, but also to increased osteoporotic activity, resulting in bone resorption. Chemotherapy, even when successful, does not produce skeletal healing, and the dual risks of osteopenia and pathologic fracture persist. Fortunately, this often grim situation has at last begun to yield to pharmacologic intervention since the administration of bisphosphonates has been found to reduce the bone destruction caused by multiple myeloma.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Multiple Myeloma.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only